Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon

Novo Nordisk A/S TodayNVONovo Nordisk A/S$108.47 +0.46 (+0.43%) 52-Week Range$99.42▼$148.15Dividend Yield0.66%P/E Ratio35.10Price Target$150.40Add to WatchlistRecent sales of a little-known stock, Madrigal Pharmaceuticals NASDAQ: MDGL, could bode well for Novo Nordisk A/S NYSE: NVO. The pharma industry giant has seen explosive sales growth for its GLP-1 agonist drug, semaglutide. Marketed through the names Ozempic and Wegovy, sales of the drugs grew 32% and 76% through the first nine months of 2024, compar ...